841 related articles for article (PubMed ID: 33001147)
1. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
3. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
4. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
[TBL] [Abstract][Full Text] [Related]
5. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
8. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
9. Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area.
Shimabuco AY; Medeiros-Ribeiro AC; Miossi R; Bonfiglioli KR; Moraes JCB; Gonçalves CR; Sampaio-Barros PD; Goldenstein-Schainberg C; Souza FHC; Prado LLD; Ugolini-Lopes MR; Yuki EFVN; Bonfa E; Saad CGS
Clinics (Sao Paulo); 2020; 75():e1870. PubMed ID: 33146355
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
11. The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
Wu CY; Chiu HY; Tsai TF
PLoS One; 2019; 14(12):e0225112. PubMed ID: 31881026
[TBL] [Abstract][Full Text] [Related]
12. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
[TBL] [Abstract][Full Text] [Related]
13. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
[TBL] [Abstract][Full Text] [Related]
15. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
16. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
van de Kerkhof PCM
Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
[No Abstract] [Full Text] [Related]
17. A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab.
Xiao Y; Mi W; Wang J; Wen D; Wang Y; Gu Y; Hao D; Yan W; Chen X; Li W
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2387-2401. PubMed ID: 37615837
[TBL] [Abstract][Full Text] [Related]
18. A review of secukinumab in psoriasis treatment.
Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
20. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
